Alcyone Therapeutics is Drug Discovery in United States that focus on developer business. Founded in 2010. They cover business area such as developer, neural intervention technology, neurological condition, an engineer amalgamation, micro-fabrication technology, advanced biomedical engineering, a core product, focus, target drug therapy, hydrocephalus, patient, chronic neuropathological condition, improved treatment.
2010
( 14 years old in 2024 )
Developer
-
116 John Street
Suite 300
Lowell, MA 01852
United States
Private
developerneural intervention technologyneurological conditionan engineer amalgamationmicro-fabrication technologyadvanced biomedical engineeringa core productfocustarget drug therapyhydrocephaluspatientchronic neuropathological conditionimproved treatment
* We use standard office opening hours in near Alcyone Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Alcyone Therapeutics is Drug Discovery business from United States that founded in 2010 (14 years old in 2024), Alcyone Therapeutics business is focusing on Developer.
Alcyone Therapeutics headquarter office and corporate office address is located in 116 John Street Suite 300 Lowell, MA 01852 United States.
Alcyone Therapeutics was founded in United States.
In 2024, Alcyone Therapeutics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Alcyone Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
